Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes

AIDS Reader

Volumn 15, Issue 12, 2005, Pages

  Luber, Andrew D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acid reducing agents; Drug interactions; HIV AIDS; Protease inhibitors

Indexed keywords

ACID; ATAZANAVIR; OLIGOPEPTIDE; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE;

ARTICLE; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; TREATMENT OUTCOME;

ACIDS; DRUG INTERACTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; OLIGOPEPTIDES; PYRIDINES; TREATMENT OUTCOME;

EID: 33644801629     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Palella FJ, Delany KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Kaletra (lopinavir/ritonavir) [package insert]. North Chicago: Abbott Laboratories; April 2005.
3. Lexiva (fosamprenavir) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; June 2005.
4. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents-.April 7, 2005. Available at: http://www.aidsinfo.nih.gov. Accessed April 23,2005.
5. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001; 15:185-194.
6. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. AIDS. 2002;16: 737-745.
7. O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Ac- quir Immune Defic Syndr. 2003;34:407-414.
8. Schiffer V, Deveau C, Meyer L, et al. Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort. HIV Med. 2004;5:326-333.
9. Luber AD, Garg V, Gharakhanian S; Vertex HIV Program Team. Survey of medications used by HIV- infected patients that affect gastrointestinal (Gl) acidity and potential for negative drug interactions with HAART. Presented at the 7th International Congress on Drug Therapy in HIV Infection; November 14-18, 2004; Glasgow, UK. Abstract P294.
10. Katzung BG. Introduction. In: Katzung BG, ed. Basic and Clinical Pharmacology. 5th ed. Norwalk, Conn: Appleton & Lange; 1992:1-4.
11. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetic (PK) effect of omeprazole on atazana vir with ritonavir in healthy subjects. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston. Abstract 658.
12. Reyataz (atazanavir) [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; June 2005.
13. Agarwala S, Eley TV, Child M, et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. Presented at the 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec City. Abstract 11.
14. Kaul S, Olszyk C, Ji P, et al. Pharmacokinetics of didanosine enteric coated capsules co-administered with atazanavir or atazanavir/ritonavir. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25,2005; Boston. Abstract 648.
15. Farthing C, Khanlou H. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. Presented at the 7th International Congress on Drug Therapy in HIV Infection; November 14-18, 2004; Glasgow, UK. Abstract P289.
16. Guiard-Schmid JB, Bonnard P, Poirier JM, et al. Nonsignificant drug interaction between atazanavir and proton pump inhibitors in ritonavir boosted regimen. Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27,2005; Rio de Janeiro. Abstract WePe3.3C18.
17. Kosel BW, Storey SS, Collier AC. Lack of interaction between atazanavir and lansoprazole. AIDS. 2005;19:637-640.
18. Chang J, Towner W, Kerrigan HL, Wang L. Evaluation of concomitant use of protease inhibitor (PI)- atazanavir (ATV) with proton pump inhibitor (PPI). Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24- 27,2005; Rio de Janeiro. Abstract WePe3.3C04.
19. Lind T, Rydberg L, Kyleback A, et al. Esomepra- zole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Titer. 2000;14:861-867.
20. Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908: a water soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Anlimi- crob Agents Chemother. 2004;48:791-798.
21. Ford SL, Wire MB, Lou Y, et al. Effects of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005; 49:467-469.
22. Shelton M, Ford SL, Wire MB, et al. Coadministration of esomeprazole (ESO) with fosamprenavir (FDV) has no impact on steady-state plasma amprenavir (APV) pharmacokinetics (APV10031). Presented at the 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec City. Abstract 24.
23. Bertz R, Chiu YL, Naylor C, et al. Lack of effect of gastric ARAs on lopinavir/ritonavir plasma concentrations in HIV-infected patients. Presented at the 7th International Congress on Drug Therapy in HIV Infection; November 14-18, 2004; Glasgow, UK. Abstract P279.
24. Videx (didanosine) [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; July 2000.
25. La Porte C, Aarnoutse R, Koopmans P, et al. Pharmacokinetic and food effect study of once daily indinavir/ritonavir with once daily enteric coated didanosine. Presented at the 4th International Workshop on Clinical Pharmacology of HIV Therapy; March 27-29,2004; Cannes, France. Abstract 3.2.
26. Burger DM, Hugen PW, Kroon FP, et al. Pharmacokinetic interaction between the PPI omeprazole and the HIV protease inhibitor indinavir. AIDS. 1998;12:2080-2082.
27. Rublein JC, Donovan BJ, Hollowell SB, et al. Effect of omeprazole (OMP) on the plasma concentrations of indinavir (IDV) in HIV-negative subjects. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17,2003; Chicago. Abstract A-1611.
28. Crixivan (indinavir) [package insert]. White- house Station, NJ: Merck and Co Inc; May 2004.
29. Viracept (nelfinavir) [package insert]. New York: Agouron Pharmaceuticals Inc; September 2004.
30. Boffito M, Carrier P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimeti- dine. J Antimicrob Chemother. 2002;50:1081-1084.
31. Invirase (saquinavir) [package insert]. Nutley, NJ: Roche Laboratories Inc; December 2004.
32. Fortovase (saquinavir) [summary of product characteristics]. UK/Ireland: Roche; July 2005.
33. Van Heeswijk R, Sabo JP, Cooper C, et al. The pharmacokinetic interactions between tipranavir/ri- tonavir 500 mg/200 mg bid (TPV/r) and atorva- statin, antacid and CYP3A4 in healthy volunteers. Presented at the 5th International Workshop on Clinical Pharmacology in HIV Infection; April 1-3, 2004; Rome. Abstract 5.2.